LifeVantage Corporation — Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2013. The request labels this “2012 Q3,” but the filing covers fiscal 2013 third-quarter results; comparisons are to the periods ended March 31, 2012.
Business context and key financial metrics
LifeVantage sells nutraceutical and personal-care products primarily through independent distributors, including Protandim, TrueScience and newly introduced Canine Health. It transitioned Japan from a “not-for-resale” model to direct selling in January 2013 and launched a Japan-specific Protandim formulation.
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Net sales | $50.4 million vs. $36.2 million | $156.7 million vs. $81.6 million |
| Gross profit | $43.5 million vs. $31.2 million | $127.3 million vs. $70.0 million |
| Gross margin | 86% in both periods | 81% vs. 86% |
| Operating income | $3.9 million vs. $6.4 million | $11.8 million vs. $14.1 million |
| Net income (loss) | $3.4 million vs. $(4.8) million | $7.8 million vs. $7.6 million |
| Diluted EPS | $0.03 vs. $(0.05) | $0.06 vs. $0.07 |
At March 31, cash and cash equivalents were $27.2 million, current assets $43.9 million, current liabilities $18.6 million, and working capital $25.3 million. Total assets were $54.5 million and total liabilities $19.6 million. The balance sheet reports no debt balance; other long-term liabilities were $1.0 million. No debt facility availability is stated.
For the nine months, operating cash flow was $10.1 million, investing cash outflow $4.6 million, and financing cash outflow $2.8 million. Cash increased by $2.6 million from June 30, 2012. Capital expenditures were $4.6 million. Operating lease obligations totaled $19.0 million, including $2.2 million due within one year.
Changes versus prior comparable periods
- Sales rose by $14.2 million for the quarter and $75.1 million for the nine-month period, with growth in both the Americas and Asia/Pacific. Nine-month Asia/Pacific sales were $58.9 million, versus $22.0 million; Americas sales were $97.7 million, versus $59.6 million.
- Quarterly results improved from a loss to profit, while nine-month net income was slightly higher year over year. Operating income declined in both comparisons as operating expenses grew faster than gross profit.
- Nine-month gross margin fell from 86% to 81%, principally due to the Protandim recall. The filing reports $5.6 million net recall expense to date, including a $3.7 million inventory write-down; the quarter included a $461,000 reduction in product recall costs.
- Operating cash flow decreased from $11.7 million to $10.1 million. Cash at period-end increased from $24.6 million at June 30, 2012 to $27.2 million.
Outlook, commentary, risks and unusual items
- Management expects operating expenses to continue increasing as sales grow and believes cash on hand and future cash flow will fund operations for at least the next 12 months. No quantified revenue or earnings guidance is provided. Management cautions that sales shortfalls could require expense reductions or additional financing.
- Recall costs remain uncertain; the company says ultimate financial, reputational and other effects are not known. The recall followed concerns that some tablets may contain small metal fragments from turmeric extract. The company does not maintain product recall insurance.
- A distributor sued the company in Utah on April 9, 2013, alleging breach of agreement and trade-secret misappropriation, and seeking more than $20 million. The company calls the allegations without merit and intends to defend the case.
- Key risks include Japanese regulatory requirements and acceptance of the new product formulation and selling model, distributor compliance and retention, product quality and recall exposure, third-party manufacturing and raw-material supply, foreign currency movements, and dependence on consumer confidence and product reputation.
- The company repurchased 2.0 million shares for $4.9 million during the nine months and announced an additional authorization to repurchase up to $5 million. A $363,000 business-development incentive partly offset foreign-currency losses in other income/expense.
- Cash balances exceeded federal insurance limits; $17.5 million was held primarily at one financial institution and $10.0 million at another. Disclosure controls were reported effective as of March 31, 2013.
Important facts for investors to verify
- Actual total cost and business impact of the Protandim recall, including insurance recoveries, returns and any lingering product-quality concerns.
- Whether Japan’s direct-selling transition and reformulated Protandim sustain sales while meeting local regulatory requirements.
- Sales growth quality and expense trends, particularly distributor commissions, headcount and professional fees, given declining operating income.
- Cash generation, liquidity needs, and the effect of share repurchases and future financing on cash and dilution.
- Developments, potential exposure and any subsequent resolution of the distributor lawsuit seeking more than $20 million.